EBIT Margin (Annual)

EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues

BridgeBio Pharma, Inc. (BBIO) had EBIT Margin of -104.25% for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$502.08M
Net Income	$-724.93M
Cost of Goods Sold	$20.96M
Gross Profit	$481.11M
Operating Expenses	$1.03B
Operating Income	$-523.41M
Non-Operating Income/Expense	$-209.09M
Pre-Tax Income	$-732.50M
Normalized Pre-Tax Income	$-732.50M
Income after Taxes	$-732.94M
Income from Continuous Operations	$-732.94M
Consolidated Net Income/Loss	$-732.94M
Normalized Income after Taxes	$-732.94M
EBIT	$-523.41M
EBITDA	$-512.01M
Weighted-Average Shares Outstanding (Basic)	191.53M
Weighted-Average Shares Outstanding (Diluted)	191.53M
Earnings per Share (EPS) (Basic)	$-3.78
Earnings per Share (EPS) (Diluted)	$-3.78
Balance Sheet Financials
Current Assets	$797.75M
Property, Plant, and Equipment	$5.37M
Long-Term Assets	$138.28M
Total Assets	$936.02M
Current Liabilities	$287.97M
Long-Term Debt	$1.85B
Long-Term Liabilities	$2.72B
Total Liabilities	$3.01B
Common Equity	$-2.08B
Tangible Shareholders Equity	$-2.10B
Shareholders Equity	$-2.08B
Common Shares Outstanding	194.77M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-445.91M
Cash Flow from Investing Activities	$-24.49M
Cash Flow from Financial Activities	$359.29M
Beginning Cash	$683.24M
End Cash	$572.14M
Increase/Decrease in Cash	$-111.10M
Stock-Based Compensation	$133.02M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.77
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-8.29
Debt to Equity Ratio	-0.89
Gross Margin	95.82%
Operating Margin	-104.25%
EBIT Margin	-104.25%
EBITDA Margin	-101.98%
Pre-Tax Profit Margin	-145.89%
Profit Margin	-144.39%
Free Cash Flow	$-447.01M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.54
Inventory Turnover	0.78
Receiveable Turnover	3.60
Days Sales in Receivables	101.37
Return on Equity	35.31%
Return on Tangible Equity	34.83%
Return on Assets	-78.30%
Return on Investments	327.88%
Book Value Per Share	$-10.66
Free Cash Flow per Share	$-2.33
Operating Cash Flow per Share	$-2.33

Data from Zacks Investment Research, Inc.